Navigation Links
Eshelman Ventures Leads and Closes Series A Round in Asepticys, Inc., a Development Stage Company Focused on Developing Novel Media Disinfection Solutions.

Asepticys, Inc., is pleased to announce the closing of its series A round of financing with Eshelman Ventures, LLC in Wilmington, NC. “Eshelman Ventures is excited at the tremendous opportunity that Asepticys brings to the market, with truly disruptive potential in the Contact Lens Solutions market as well as numerous other applications in the health and wellness verticals’” says Fred Eshelman.

Asepticys is developing a new generation of chemically unique medical disinfection solutions that are effective across a broad spectrum of microbial pathogens and clinically beneficial in numerous medical and consumer healthcare applications.

The medical disinfection solutions contain a unique combination of sterilizing agents, creating a multiple stressor environment that kills and deactivates pathogenic organisms across all microbial kingdoms. This approach is materially different than selective disinfection using either single or dual stressors (e.g., chlorhexidine derivatives), which is currently the standard of care in medical/clinical healthcare. The disinfection solutions are minimally reactogenic and gentle enough for numerous clinical applications including topical skin disinfection, ophthalmologic, surgical, urology catheter, venous catheter and needleless IV connectors, and trauma, wound and burn site maintenance.

The disinfection solutions have been specifically engineered for clinical use and could dramatically reduce hospital-acquired and consumer healthcare-related infection, as well as improve patient outcome via reduction of nosocomial infection in postsurgical/treatment maintenance while in hospital.  According to Chad Roy, CEO, Asepticys, Inc., “At a time when the medical community, CDC and FDA are closely following public health issues in these areas and considering revisions to applicable standards, we believe this is the game-changer the contact lens solution market has been anticipating for over 30 years. This will disrupt and change the game not only in the contact lens solutions market, but in numerous applications around the world requiring sterilization.”

About Eshelman Ventures

Eshelman Ventures LLC, founded by Fred Eshelman was founded as an investment company primarily interested in private healthcare companies. Located in Wilmington, NC, Dr. Eshelman previously founded and served as CEO and Executive Chairman of Pharmaceutical Product Development prior to its sale to private equity interests as well an a number of other companies. For more information on Eshelman Ventures LLC and its investment portfolio visit

About Asepticys, Inc.

Asepticys is developing new generation chemically unique medical disinfection solutions that are effective across a broad spectrum of microbial pathogens and clinically beneficial in numerous medical and consumer healthcare applications.

We are currently focused on development of a multipurpose contact lens disinfection solution (MPDS) to be used regularly as a broad-spectrum sterilizer for daily use lens. Our solution is gentle enough to be used daily, requires minutes for complete sterilization of the lens, and is isotonically balanced for comfort. Also, because of unique combination of sterilants in our formulation, the risk of unwanted biofilm formation in cleaning/storage CL containers is essentially eliminated. For more information on Asepticys visit


Read the full story at

Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved

Related biology technology :

1. PharmaVentures Advises 3Legs Resources on its Acquisition of the Immuno-Oncology Company SalvaRx Who Announced its Admission for Trading on AIM Today
2. VisionGate Receives Strategic Investment from Trinnovate Ventures
3. PharmaVentures Advises Transgene on the Sale of Their Biopharmaceutical Manufacturing Plant
4. Flagship Ventures Brian Fiske Named To Forbes 30 Under 30 List
5. WuXi Healthcare Ventures Joins Financing Rounds for Twist Bioscience and Syros Pharmaceuticals
6. Ping An Ventures Takes Equity Stake in 20/20 GeneSystems
7. Clarus Ventures Adds Kiran Reddy, Robert DeBenedetto, and Lazar Dimitrov to Investment Team
8. BioPact Ventures, LLC Announces Appointment of Joe Dillon as Chief Executive Officer
9. PCI Ventures Company Liquid Biotech USA, Inc. Announces Raising $2M in Seed Capital to Develop its Proprietary Platform Technology for Cancer Diagnostics and Gene Discovery
10. ARCH Venture Partners, Flagship Ventures and MD Anderson Collaborate to Launch Codiak BioSciences
11. Turnstone Biologics Completes Series A Financing Led by Versant Ventures, Strengthens Management Team
Post Your Comments:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... compared the implantation and pregnancy rates in frozen and fresh in vitro ... of progesterone and maternal age to IVF success. , After comparing the results ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee ... honoring scientists who have made outstanding contributions to analytical chemistry and applied ... the world’s leading conference and exposition for laboratory science, which will be held ...
Breaking Biology Technology:
(Date:7/20/2017)... 2017 Delta (NYSE: DAL ) customers now can ... at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan ... Delta,s biometric boarding pass experience that ... now integrated into the boarding process to allow eligible Delta SkyMiles Members ...
(Date:6/14/2017)... June 15, 2017  IBM (NYSE: IBM ) is introducing ... event dedicated to developing collaboration between startups and global businesses, ... 15-17. During the event, nine startups will showcase the solutions ... various industries. France ... market, with a 30 percent increase in the number of ...
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
Breaking Biology News(10 mins):